The MMRF Precision
The MMRF constructed a unique model to break down barriers to traditional cancer research. It differentiates the MMRF by providing the only end-to-end solution in cancer research. It is based on three interrelated pillars: The Data Bank, The Learning Network and The Clinic. It is fueled by information and data sharing, collaborative expertise, technology, speed and urgency. Applying this innovative model to precision medicine—getting patients the right treatment at the right time—puts the promise of a cure within reach. It is the most effective approach in cancer research today.
The MMRF is the only organization that has built an end-to-end cancer research system to facilitate and accelerate the entire process. It unites many disparate entities: industry, academia, biotechs, clinics, researchers, the FDA, the NIH, caregivers and patients – the Cancer Archipelago℠. This unique model is being emulated for other disease research.
Click on areas of the precision model below to learn more about each section.
The Data Bank: Data Generation and Integration
It all starts with the data, so we created unique ways to generate it, gather it, decode it, and track it over time. The MMRF Data Bank is a goldmine of longitudinal genomic and clinical data
Recognizing that precision approaches in oncology require the generation, centralization and analysis of large amounts of top quality clinical and molecular data, the MMRF built a robust Data Bank that makes it possible for the global research community to work as one. The Multiple Myeloma Genomics Initiative (MMGI) allowed the MMRF and its partners to be the first to sequence the myeloma genome. We next launched the MMRF CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) Study, the most expansive and comprehensive longitudinal genomic research study ever conducted in myeloma and a landmark initiative in the field of cancer research. Collaborating with best in class partners like Translational Genomics Research Institute and the Broad Institute, we are beginning to uncover deeper insights into the disease’s biology that revealed a more complete understanding of patients’ responses to treatments, leading to a better understanding of disease progression and greater insights for the development of personalized treatments.
The Learning Network: Collaboration and Discovery
By pushing our valuable data to the public domain and creating incentives for academia and industry to share their learnings, we accelerate research and discovery.
While many research organizations carefully safeguard their data until publication—a process that can take years—the MMRF has made it a priority to openly and freely share its data, through a global Learning Network. This has allowed brilliant minds from all corners of the scientific community to work collaboratively to decipher patterns for further exploration. The Learning Network was built to democratize data, allowing researchers and clinicians worldwide to share and contribute to a growing knowledge base that can be used to generate hypotheses for clinical trials and explore new and potentially more effective ways of treating myeloma. The MMRF Researcher Gateway provides researchers worldwide access to the data and tools in the Gateway to identify new targets, pathways, and biomarkers, as well as develop hypotheses for new clinical trials. The MMRF CoMMunity Gateway is a patient-centered informational and social platform aimed at empowering patients in managing their care, helping guide patient choices and providing micro-communities focused on their particular type of myeloma.
The Clinic: Accelerating Trials
Data and learning produce treatments to be tested. Our own clinical network, the Multiple Myeloma Research Consortium, helps us speed promising new therapies to trial, and the patients who need them.
To drive treatments quickly and effectively into the hands of patients, the MMRF built a first in class, worldwide network of research institutions and cancer centers (The Clinic) that has produced unprecedented results. Since the inception of the MMRF, life expectancy for multiple myeloma patients has more than tripled and 10 new treatments for multiple myeloma have received FDA approval. Never taking our foot off the accelerator, we are working closely to rapidly test an arsenal of powerful new treatments with 30 new drugs and combinations in clinical trials within our network, including immunotherapies that harness the power of patients’ own immune systems, targeted therapies that attack patients’ specific genetic mutations, and drugs that work in entirely new ways to stop cancer in its tracks. For many patients, especially those with no other options, treatment through these clinical trials has become their lifeline.